Phenobarbital Global Market Report 2026

Phenobarbital is a long-acting barbiturate medication primarily used to control and prevent seizures, especially in the treatment of epilepsy. It is also occasionally prescribed as a sedative for anxiety or to manage withdrawal symptoms. The drug enhances the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits nerve activity in the brain, producing a calming effect on the central nervous system and reducing the likelihood of seizures.

The main indications for phenobarbital are epilepsy and neonatal seizures. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures. Phenobarbital is available in various dosage forms, including tablets, capsules, and injectables, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is used in seizure management, anesthesia, sleep disorders, and alcohol withdrawal syndrome, serving a range of end users such as hospitals, clinics, research laboratories, and homecare settings.

Tariffs have influenced the phenobarbital market by increasing the cost of imported active pharmaceutical ingredients and synthesis intermediates used in drug manufacturing. These impacts are most evident in generic drug manufacturing regions across Asia Pacific and Latin America, where producers rely on cross border sourcing for essential inputs. Rising tariff related expenses have increased overall production costs and pressured pricing strategies for antiepileptic drugs. This has influenced procurement planning and supply availability in both public and private healthcare channels. However, tariffs have encouraged domestic API production, expanded local manufacturing capacity, and improved long term supply security.

The phenobarbital market research report is one of a series of new reports from The Business Research Company that provides phenobarbital market statistics, including phenobarbital industry global market size, regional shares, competitors with a phenobarbital market share, detailed phenobarbital market segments, market trends and opportunities, and any further data you may need to thrive in the phenobarbital industry. This phenobarbital market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The phenobarbital market size has grown steadily in recent years. It will grow from $1.54 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to long-standing clinical efficacy, widespread availability in essential medicine lists, high prevalence of epilepsy, use in neonatal care, affordability compared to newer drugs.

The phenobarbital market size is expected to see steady growth in the next few years. It will grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to continued demand in low-resource settings, expansion of generic manufacturing, growth in neonatal intensive care units, rising epilepsy diagnosis rates, focus on essential medicines access. Major trends in the forecast period include continued use in epilepsy and neonatal seizure management, increasing availability of generic phenobarbital, growing focus on cost-effective anticonvulsant therapies, expansion of hospital-based seizure management, rising monitoring of long-term drug safety.

The rising prevalence of epilepsy is expected to drive the growth of the phenobarbital market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. The increasing prevalence is largely due to greater awareness, as more individuals recognize symptoms and seek medical evaluation, leading to higher reported cases. Phenobarbital is effective in managing epilepsy as an anticonvulsant medication that slows neuronal activity in the brain, helping to prevent and control seizures. For example, in February 2024, the World Health Organization, a Switzerland-based international public health agency, reported that approximately 50 million people worldwide were living with epilepsy, confirming its status as one of the most common neurological disorders globally. Consequently, the growing prevalence of epilepsy is expected to support the expansion of the phenobarbital market.

Major companies operating in the phenobarbital market are focusing on developing innovative formulations, such as phenobarbital sodium, to enhance treatment efficacy and safety. Phenobarbital sodium is the sodium salt form of phenobarbital, primarily used as an anticonvulsant and sedative. It is commonly prescribed to manage seizures, particularly in epilepsy, as well as to treat anxiety, insomnia, and occasionally to induce sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates. This formulation is free from benzyl alcohol and propylene glycol, making it safer for use in newborns. SEZABY received orphan drug designation and is supported by clinical data demonstrating its effectiveness in controlling neonatal seizures, addressing a critical unmet need in this vulnerable patient population.

In September 2023, Pharmanovia Limited, a UK-based healthcare lifecycle management company, acquired the central nervous system (CNS) portfolio of Sanofi S.A. for an undisclosed amount. Through this acquisition, Pharmanovia aims to strengthen and expand its neurology/CNS franchise by pursuing market growth and product diversification, while leveraging its lifecycle-management expertise to maintain and advance established CNS therapies. Sanofi S.A. is a France-based healthcare company specializing in the research, development, and commercialization of prescription medicines and vaccines worldwide.

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd.

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the phenobarbital market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phenobarbital market consists of sales of products including phenobarbital tablets, phenobarbital oral elixir, phenobarbital injectables, veterinary phenobarbital products, and combination medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Phenobarbital Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses phenobarbital market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for phenobarbital ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The phenobarbital market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Epilepsy; Neonatal Seizures
• 2) By Dosage Forms: Tablets; Capsules; Injectables
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Seizure Management; Anesthesia; Sleep Disorders; Alcohol Withdrawal Syndrome
• 5) By End User: Hospitals; Clinics; Research Laboratories; Homecare Settings
• Subsegments:
• 1) By Epilepsy: Focal (Partial) Seizures; Generalized Tonic-Clonic Seizures; Status Epilepticus; Refractory Epilepsy; Idiopathic Epilepsy
• 2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures; Intracranial Hemorrhage-Induced Seizures; Metabolic Disorders; Congenital Brain Malformations; Infections
• Companies Mentioned: Teva Pharmaceutical Industries Ltd.; Sandoz Group AG; Hikma Pharmaceuticals PLC; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Lupin Limited; Fresenius Kabi AG; Baxter International Inc.; Par Pharmaceutical Inc.; Harman Finochem Ltd.; Manus Aktteva Biopharma LLP; Shandong Xinhua Pharmaceutical Co. Ltd.; Alkaloida Chemical Company Zrt.; Yashiro Pharmaceutical Co. Ltd.; JPN Pharma Pvt. Ltd.; Pfizer CentreOne; Macleods Pharmaceuticals Ltd.; Alembic Pharmaceuticals Ltd.; Zydus Lifesciences Ltd.; Aurobindo Pharma Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.